Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India

Roy, Somnath; Ghosh, Joydeep; Ganguly, Sandip; Mondal, Debapriya; Dabkara, Deepak; Chatterji, S. N.; Biswas, Bivas

doi:10.1200/go.21.00139

Cited by 3 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When compared with other real-world experiences of the COVID-19 disease in cancer patients, our study is unique in comparing the characteristics of both waves. The most common malignancy encountered in our study was of the lungs followed by GIT and breast, which conforms with contemporary studies by Roy et al and CCC-19 literature, 7,16 however differs from the UK Coronavirus Cancer Monitoring Project (UKCCMP) data. 17 The case fatality rate in an unselected Indian population was 1.9% 8 ; however, in cancer patients, it was reported to be 6.5% in the first wave from a study in cancer patients in India.…”

Section: Discussionsupporting

confidence: 90%

“…There have been studies from India as well as the rest of the world depicting the outcomes and mortality of cancer patients affected with COVID-19. 5,6 Roy et al reported 145 patients of solid organ malignancies, of which 22 (15%) patients succumbed, 7 whereas Mehta et al reported a glaringly high CFR of 28% in cancer patients when compared to match noncancer population (14%). 8 With the vaccine roll-out drives in full swing across the world, the glaring truth is that this subgroup of patients were excluded from all vaccine trials; hence, the efficacy in the setting of malignancy remained elusive.…”

Section: Introductionmentioning

confidence: 99%

“…There have been studies from India as well as the rest of the world depicting the outcomes and mortality of cancer patients affected with COVID-19. 5 6 Roy et al reported 145 patients of solid organ malignancies, of which 22 (15%) patients succumbed, 7 whereas Mehta et al reported a glaringly high CFR of 28% in cancer patients when compared to match noncancer population (14%). 8 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 and Cancer: A Comparison of the Two Important Pandemic Waves in an Indian Cancer Patients' Cohort

Batra,

Nathany,

Sharma

et al. 2023

South Asian J Cancer

View full text Add to dashboard Cite

It is well known that patients with cancer are at an increased risk of severe COVID-19. There are no reports that depict the differences in outcomes in cancer patients between the two waves of the pandemic. This is a real-world experience aimed at characterizing the differences in demographics, clinical features, treatment details, and outcomes in COVID-19-positive cancer patients between the two pandemic waves. This was a prospective study of all COVID-19-positive cancer patients attending our specialty out-patient department at Rajiv Gandhi Cancer Institute and Research Centre between March 2020 and November 2020 (1st wave) and April 2021 and June 2021 (second wave). All patients diagnosed to have COVID-19 by real-time polymerase chain reaction (RT-PCR) with a biopsy-proven solid organ malignancy attending the medical oncology out-patient department were included during both the waves. A total of 300 patients with proven SARS-CoV-2 infection by either RT-PCR or cartridge based nucleic acid amplification test were encountered, of which 123 were encountered during the first wave of the pandemic and 177 during the second wave. The case fatality rate of the first wave was 9.8%, with a 15-day case fatality rate of 5.6%, whereas for the second wave, it was 13% and 7.2%, respectively. Twelve patients succumbed to COVID-19 disease in the first wave and 23 succumbed in the second. There were no statistically significant correlations; however, the death in the second wave tended to occur more in younger male patients, with comorbidities and history of smoking. There was no relation with ongoing cancer-directed treatment or chemotherapy. Our study is unique in comparing characteristics of the two most important COVID-19 waves and treatment patterns in cancer patients from a single center. The second wave showed a higher CFR, hospital admission rate, and higher frequency of respiratory complications; however, there was no relation to cancer-directed therapy and COVID-19, thus reiterating the fact that cancer treatment should not be halted in the event of a COVID-19 infection.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 and Cancer: A Comparison of the Two Important Pandemic Waves in an Indian Cancer Patients' Cohort

Batra,

Nathany,

Sharma

et al. 2023

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

“…22 The median duration to negative RT-PCR test in cancer patients after COVID infection was 16 days in 88 Indian patients with solid organ cancers. 23 To understand the effect of delaying cancer treatment in view of avoiding COVID infection, a Markov-model-based analysis was conducted for women at risk of cervical cancer in India. It was seen that there was a lifetime increase of about 795 to 2160 (2.52-3.80%) cervical cancer related deaths due to delay in treatment ranging from 9 weeks to 6 months, respectively.…”

Section: Acceptable Delay In Gynecologic Cancer Surgerymentioning

confidence: 99%

“… 22 The median duration to negative RT-PCR test in cancer patients after COVID infection was 16 days in 88 Indian patients with solid organ cancers. 23 …”

Section: Introductionmentioning

confidence: 99%

Management of Gynecologic Cancer During COVID-19 Pandemic: South Asian Perspective

Singh

Mishra

Jayraj³

et al. 2022

Cancer Control

View full text Add to dashboard Cite

Management of gynecological cancers has suffered during the pandemic, partly due to lockdown and partly due to directing resources to manage COVID-19 patients. Modification of gynecological cancer management during this pandemic is recommended. Cervical cancer patients who present with stage IA1 disease can have a delay of up to 8 weeks for surgical treatment, considering the slow tumor growth rate. Women with stages IA2, IB1, IB2, IIA1 must undergo radical hysterectomy and lymphadenectomy within 6 to 8 weeks. In areas where surgical treatment is not available, patients should be referred for radiation therapy/areas with adequate surgical expertise. The surgical option is attractive for early cancers during the COVID era, as it involves a single visit compared to the multiple visits required for chemoradiation. The value of lymph node staging needs to be reconsidered. Neoadjuvant chemotherapy should be given preference over primary cytoreductive surgery for advanced ovarian cancers. Surgeries, which demand extended surgical time such as Hyperthermic Intraperitoneal Chemotherapy and pelvic exenterations, should be avoided during this pandemic. For patients scheduled for interval surgery after two or three neoadjuvant cycles, six cycles of chemotherapy should be considered before surgery is performed. For early-stage, low-grade endometrial cancer, consideration should be given to medical management until surgery is possible. The above recommendations have been made keeping in mind the geography, patient load, and availability of resources available to health care providers from southeast Asia. They might not be applicable globally and every practitioner should take call regarding patient’s management as per availability of resources and loco-regional circumstances. The implementation of recommended international guidelines for the management of gynecologic cancers should take precedence. Each modification to the standard approach should be approved by a multidisciplinary team depending on the condition of the patients and the locoregional circumstances.

show abstract

Insights into cancer characteristics among SARS-CoV-2 infected hospitalized patients: a comprehensive analysis from the National Clinical Registry for COVID-19

Chatterji,

Turuk,

Das

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Cancer outcome is dependent on multiple predetermining factors including cancer, type of cancer and its related factors. This study aims to investigate the association between COVID-19 & cancer/cancer types, focusing on risk of in-hospital mortality within 30 days of hospitalization of COVID-19 patients with cancer. Materials and methods We did a registry (National Clinical Registry for COVID-19) based retrospective observational study including 51,544 patients, of whom 976 were patients with cancer, admitted with COVID-19 between August 2020 and August 2023 across 42 hospitals of India. Results Out of 51,544 patients, 976 (1.8%) had cancer. Hematological malignancies made up 15.06% (147 cases), while solid cancers accounted for 29.5% (288 cases), with genitourinary (18.4%, 80 cases), gastrointestinal (15.2%, 49 cases), and lung cancers (10.1%, 34 cases) being the most common. Solid cancers had the highest in-hospital mortality rate at 25%. Survival analysis showed that cancer-related hazards were highest at admission but decreased to levels comparable with other morbidities within nine to ten days. For each cancer type, the hazard was significantly elevated compared to that of the cancer-free (Other Comorbidities and No Comorbiditiy) groups during the initial period of hospitalization. The use of Remdesivir, steroids, and anticoagulants reduced mortality risk, and prior COVID-19 vaccination was protective against mortality across all cancer types. Conclusion This study shows that both cancer in general and specific cancer types significantly increase the risk of severe outcomes among SARS-CoV-2-infected patients, especially immediately after hospitalization. The findings highlight the need for close monitoring and personalized interventions for COVID-19 patients with cancer for at least 10 days post-hospitalization, with a more specific high-risk period ranging from 7 to 18 days depending on the type of cancer. Supplementary Information The online version contains supplementary material available at 10.1007/s00432-024-05966-1.

show abstract

Outcome of COVID-19 in Solid Organ Malignancies: Experience From a Tertiary Cancer Center in Eastern India

Cited by 3 publications

References 16 publications

COVID-19 and Cancer: A Comparison of the Two Important Pandemic Waves in an Indian Cancer Patients' Cohort

COVID-19 and Cancer: A Comparison of the Two Important Pandemic Waves in an Indian Cancer Patients' Cohort

Management of Gynecologic Cancer During COVID-19 Pandemic: South Asian Perspective

Insights into cancer characteristics among SARS-CoV-2 infected hospitalized patients: a comprehensive analysis from the National Clinical Registry for COVID-19

Contact Info

Product

Resources

About